ELIMINATE-B Phase 1 dose finding study for chronic Hepatitis B ... genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure.

These problems can be best addressed by systematic studies of antigen three-dimensional structure ... because HBV could not be cultivated outside patients. Recombinant DNA technology allowed ...

KRIBB hosts the Center for Functional Analysis of the Human Genome (Daejeon ... a Saccharomyces cerevisiae-derived recombinant hepatitis B surface antigen vaccine. In November 1992, the firm ...

Hepatitis B and C still survive in the dark, driven by a lack of information, unhygienic medical procedures, and poor access ...

Scientists discovered a way to block hepatitis B infection using an anticancer drug, offering hope for new treatments.

Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

Therefore, a better treatment is needed. A crucial HBV protein called X is necessary for the virus to establish an infection in a host cell, and viral gene expression. But since X gene is in the viral ...

Researchers showed how what appears to be a tangle of DNA is actually organized into a structure that coordinates thousands of genes to form a sperm cell. The work, published as two papers in ...

Hepatitis B virus (HBV) is the leading cause of cirrhosis, hepatocellular carcinoma, and liver-related death globally.1,2 The highest prevalence is found in low-income and middle-income countries ...

However, I was fascinated to discover that viruses like hepatitis B hijack epigenetic mechanisms, even using human DNA-packaging proteins to regulate their activity.” Not long after, study first ...

Bacteriophages, the most abundant life form on Earth, infect bacterial cells and influence the structure of the microbial ...